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Accepted 11 April 2019Background: The advent of bioresorbable vascular scaffolds (BVS)was considered as a potential improvement in percuta-
neous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clin-
ical performance, long-termsafetyandefficacyofBVS incomplexcoronary lesions remainuncertain.COMPAREABSORB, a
multicenter, single blind, prospective randomized trial, aims to compare the clinical outcomes between the Absorb BVS
and Xience everolimus-eluting metallic stent (EES) in patients with coronary artery disease and a high risk of restenosis.
Design: COMPARE ABSORB is designed to enroll 2100 patients at up to 45 European sites. Enrolled patients will possess
high risk for restenosis due to clinical profile or coronary lesion complexity and will undergo elective or emergent PCI.
Once included in the study, patients will receive either Absorb BVS or Xience EES. Specific advice on implantation tech-
nique including mandatory pre-dilatation, sizing and post-dilatation (PSP), will be used in the Absorb BVS arm. The pri-
mary endpoint is target lesion failure (TLF), a device-oriented composite endpoint (cardiac death, target vessel
myocardial infarction and clinically-indicated target lesion revascularization). The trial is powered to assess non-
inferiority of Absorb BVS compared with Xience EES with a predetermined non-inferiority margin of 4.5% at 1 year after
index procedure. The clinical follow-upwill continue for 7 years.
Conclusions: Theprospective COMPAREABSORB randomized trial (ClinicalTrials.govNCT02486068)will help to assess the
long-term safety and efficacy of Absorb BVS comparedwith Xience EES in the treatments of patients with complex coro-
nary artery disease and a high attendant risk of restenosis.
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The implantation of a bioresorbable scaffold is a transformative ap-
proach to the treatment of coronary atherosclerosis, liberating the coro-
nary artery from permanent metallic caging. Theoretically, the vessel
wall, is able to remodel and exhibit plaque reduction in response to
pharmacological treatment and physiological stimuli, but this can only
occur in the absence of a permanent implant [1–3]. In patientswith sim-
ple lesions, the ABSORB cohort A and B first-in-man trials showed clin-
ical safety up to 5 years with potential late benefits of bioresorbable
vascular scaffold (BVS) implantation, such as lumen enlargement,
plaque reduction and restoration of vasomotion. These phenomena
start to appear from 1 to 2 years after implantation of the BVS in the
early phase of bioresorption [4–7]. After thefirst-in-man studies, Absorb
BVS was compared with Xience EES in relatively low-risk lesions and
patients in 4 randomized trials: ABSORB II, ABSORB III, ABSORB Japan
and ABSORB China, with hard clinical primary endpoints. Although the
Absorb BVS met the criteria for non-inferiority compared with Xience
EES in the first year after implantation [8], an increased risk of adverse
events after 1 year has been reported [9,10]. Subsequently, the all-
comers AIDA trial, originally designed to investigate non-inferiority of
the Absorb BVS in 2-year target vessel failure rate compared with
Xience EES, was stopped early due to safety concerns, with 2-year defi-
nite or probable device thrombosis rates significantly higher in the Ab-
sorb BVS arm than in the Xience EES armdespite no overall target vessel
failure hazard difference [11]. Simultaneously, an individual patient-
level pooled meta-analysis of 4 randomized Absorb trials identified
that Absorb BVS was associated with a higher 3-year rate of TLF than
Xience EES, drivenby an increased rate of scaffold thrombosis and target
vesselmyocardial infarction [12]. Consequently, an ESC-EAPCI task force
stated that the current BVS should not preferred to conventional DES in
clinical practice [13,14]. Based on these early warning signals, the use of
Absorb BVS was restricted to centers participating in clinical studies
since May 31, 2017.
However, there undoubtedly exists a clear relationship between im-
plantation techniques and observed clinical outcomes, identified both in
the GHOST-EU registry [15] and in particular the 4 Cities study [16],
where development of a ‘BVS-specific’ implantation technique signifi-
cantly reduced scaffold thrombosis rates. A pooled analysis of Absorb
trials confirmed that aggressive pre-dilation and optimal post-dilation
were independent predictors of freedom from scaffold thrombosis or
TLF respectively between 1 and 3 years, suggesting that an optimal
PSP (Pre-dilation, Sizing and Post-dilatation) techniquewas strongly as-
sociated with improved Absorb BVS-related outcomes during 3-year
follow-up [17].
In previous Absorb trials, as well in the AIDA trial, the “PSP” implan-
tation technique was neither fully developed nor adopted as part of the
study design. Whether using optimal “PSP” implantation techniques
with the Absorb BVS could reduce adverse events, especially the risk
of scaffold thrombosis, in comparison to the Xience EES, requires further
examination.
In the era of DES, in-stent restenosis, neoatherosclerosis and late
catch-up phenomenon remain unmet needs in the treatment of coro-
nary artery disease, especially for patients presenting with high risk of
restenosis. The advent of BVS technology provides the hope of transient
vessel support with drug delivery capability, potentially without the
limitations of permanent metallic implants [18,19] and freedom from
restenosis after complete bioresorption.2. Study objectives
Knowing that the TLF rate for metallic drug-eluting stents (DES)
continues to accumulate over the years and that this linear progression
of TLF is more prominent in high risk lesions and patients, it is hypoth-
esized that the use of BVS specifically might be of more benefit on thelong-term in comparison to current metallic DES, especially after com-
plete bioresorption.
Second, the previous mentioned trials (ABSORB II, III, Japan, China
and AIDA) all started with an initial conservative implantation tech-
nique using smaller sized pre-dilatation balloons, limited use of intra-
vascular imaging for optimal sizing, specifically in smaller vessels and
using smaller post-dilatation balloons and with lower post-dilatation
pressures. The COMPARE ABSORB trial will benefit from such initial ex-
periences and is one of the first trials with Absorb BVS in which both a
specific PSP implantation technique has been implemented in the pro-
tocol from the start, and that includes only experienced operators/cen-
ters for enrollment. One of the purposes of the current investigation is
therefore to prove the short-term equivalence and long-term benefit
of the Absorb BVS over Xience EES in patients at high risk of restenosis
with complex lesion(s) using up-to-date implantation techniques.
3. Randomization and trial management
The COMPARE ABSORB trial is a prospective, single-blind, with a 1:1
balanced randomization, controlled, multicenter study in 45 European
sites. This trial is designed to enroll 2100 patients and it is anticipated
that 1050 patients will be treated with the Absorb BVS and 1050 pa-
tients will be treated with the Xience EES (Abbott Vascular, Santa
Clara, CA). Randomization will be performed via web-based software
with random blocks according to center. Randomization will occur
after all inclusion criteria are met and no exclusion criteria are present,
and as soon as the baseline angiographic assessment confirms that the
patient matches enrolment criteria and after the guide-wire has suc-
cessfully passed the first target lesion. Treatment of non-target lesions
during the index procedure was allowed, if this was done successfully
and without complication before initial treatment of the first target le-
sion. All target lesions for each patient treated at the index and staged
procedure will receive the same assigned stent type according to ran-
domization. Medical teams responsible for care of the patients during
the procedure and their hospital stay were instructed not to tell or
write in the procedure report or discharge letter the treatment group
to which the patients had been assigned for accurate interpretation of
patient-reported outcomes. All data will be entered into a secure web-
based data capture system (Clinigrid, Paris, France). An independent
clinical research organization (CERC, Massy, France) will monitor the
trial by site visits and remotemonitoring. Source data verification on in-
formed consent, endpoint related events and follow-up will be per-
formed for 100%. Source verification for base-line data will be
performed for 50%. Adverse clinical events will be adjudicated by an in-
dependent Clinical Event Committee, and clinical/angiographic data an-
alyzed by an independent angiography core lab and statistical
department (Cardialysis, Rotterdam, The Netherlands). For clinical
oversight and daily operations of the trial a Steering Committee and Ex-
ecutive Committee, respectively, has been appointed.
An independent Data Safety and Monitoring Board will monitor the
individual and collective safety of the patients in the study during enrol-
ment phase and up to 1 year of follow-up (primary endpoint). The pa-
tients will be followed through 7 years to assess the clinical status and
major clinical events (Fig. 1).
4. Patient population
Patients aged 18–75 years with symptomatic ischemic heart disease
and presence of high-risk features for restenosis due to clinical profile or
coronary lesion complexity and who are scheduled to undergo elective
or emergent PCI are potential candidates to participate in this study.
Subjects participating in the study must meet at least one of the inclu-
sion criteria: medically treated diabetes, or multivessel disease with
N1 de-novo target lesions and/or presence of at least one complex target
lesion. Subjects who meet any of the exclusion criteria are not allowed




1. Age b 18 years, or N 75 years
2. Patients incapable of giving informed consent
3. Patients under judicial protection, tutorship or curatorship
4. Known comorbidities which make patients unable to complete 7 years of
follow-up
5. Female of childbearing potential (and last menstruation within the last




8. Known intolerance to aspirin, heparin, PLLA, everolimus, contrast material
9. Cardiogenic Shock (Killip N2)
10. PCI with implantation of stents/scaffolds within previous 30 days.
11. Active bleeding or coagulopathy
12. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint
13. Renal insufficiency (GFR b45 ml/min)
579C.C. Chang et al. / Cardiovascular Revascularization Medicine 20 (2019) 577–582to enter the study. Inclusion and exclusion criteria are listed in Tables 1
and 2, respectively.
5. Patient information and informed consent
Prior to study start, investigatorswill obtainwritten IRB/Ethics Com-
mittee approval for the study and the patient information/informed
consent form. Only patients with signed or witnessed oral consent dur-
ing primary PCI can be included. In case of witnessed oral consent, writ-
ten consent will be obtained after the initial procedure. Study patients
will be assured that they may withdraw from the study at any time
and for any reason with prejudicing medical care.
6. Study endpoints
The study primary endpoint is target lesion failure (TLF), defined as a
composite of cardiac death, myocardial infarction (MI) in target vesselTable 1
Inclusion criteria.
Inclusion criteria
Patients aged 18–75 years with at least one of the following:
1. High-risk characteristics for restenosis
• Medically treated diabetes (oral medication or insulin) and/or multivessel
disease of which more than one de-novo target lesion to be treated with the
study scaffold/stent
2. Complex target lesion
Single de-novo target lesion satisfying at least one of the following:
• Lesion length N 28 mm
• Small vessels: Target lesion reference vessel diameter ≥ 2.5 mm and
≤ 2.75 mm
• Lesion with pre-existing total occlusion (pre-procedural TIMI = 0)
• Bifurcation with single stent strategy
14. Life expectancy b7 years
15. Known non-adherence to dual antiplatelet therapy
16. Patients on oral anticoagulation therapy (including novel oral anticoagulant
such as dabigatran, rivaroxaban, apixaban and edoxaban)
17. Known Impaired left ventricular function (left ventricular ejection fraction
b30%).
18. Patients at high bleeding risk who are not suitable for long-term DAPT.
19. Following lesion characteristics:
o Target lesion with reference vessel diameter (RVD) b 2.50 mm and N 4 mm
o STEMI with RVD of N3.5 mm of the culprit target lesion
o Target lesion with in-stent/scaffold thrombosis
o Graft lesions as target lesions
o Lesion involving left main trunk
o Severe tortuosity of target vessel
o Aorto-ostial lesion(s)
o In-scaffold/in-stent restenosis
o Bifurcation target lesion with intended 2 stent/scaffold strategy
20. Non-target lesion and target lesion in the same epicardial coronary artery
(right coronary artery, left circumflex artery or left anterior descending
artery)
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for Cardiovascular Angiography and Interventions (SCAI) consensus
definition will be used to adjudicate peri-procedural MI occurring
within 48 h after the index procedure, while the Third Universal defini-
tion will be used for spontaneous MI [20,21].
7. Study hypotheses
The following hypotheses will be tested in this study, with the pri-
mary hypotheses tested hierarchically.
A. Primary hypotheses
• Hypothesis I (short term) Absorb BVS is non-inferior to Xience EES
in terms of TLF at 1 year.
• Hypothesis II (long term) Absorb BVS is superior to Xience EES in
terms of TLF between 3 and 7 years (in a landmark analysis after
3 years)
• Additional hypothesis (long term) Absorb BVS is superior to Xience
EES in terms of cumulative TLF rate at 7 years
B. Secondary hypothesis
Absorb BVS is superior to Xience EES in terms of cumulative inci-
dence of angina at 1 year.
In case non-inferiority of hypothesis I is not met, hypothesis II and
the additional hypotheses will be descriptively analyzed. Hypothesis II
represents the proof of concept of fewer events after bioresorption of
a bioresorbable scaffold compared with metallic DES.
8. Sample size calculation
Detailed information regarding sample size calculations and non-
inferiority margins for the primary hypothesis are as follows (Other de-
tails are provided in Appendix):
9. Primary Hypothesis I
From review of previous randomized trials [22], the 1-year TLF rate
for Xience EES is estimated at 8.5%. Hypothesis I (non-inferiority at
1 year) will be tested with a non-inferiority boundary of 4.5%. The re-
quired sample size is 2 × 808=1616 patients for non-inferiority testing
at 1 year with a power of 90% (α = 0.05, two sided).
10. Statistics
All clinical data will be analyzed according to the intention-to-treat
principle. For primary endpoint analysis, the hypothesis I (non-inferior-
ity in TLF at 1 year)will be tested using the standard normal distribution
and a two-sided 95% confidence interval for the difference in the target
lesion failure Kaplan-Meier rates of the Absorb BVS and Xience EES
groups. The follow-up of patients that have withdrawn informed con-
sent, that are lost to follow-up, or that have died of a non-
cardiovascular cause, will be censored at the data of the last contact.
The null-hypotheses of inferiority of the Absorb BVS (relative to the
Xience EES)will be rejected if the 95%-CI excludes the value of 4.5%. Hy-
pothesis II (superiority of theAbsorb BVS between 3 and 7 years)will be
tested by comparing the post-landmark Kaplan-Meier curves to 7 years
with the log-rank test. Binomial variableswill be evaluatedwith Fisher's
exact probability tests. Continuous variables will be tested with a two-
sample t-test or with the Mann-Whitney U test when data are not nor-
mally distributed. The full data analytic methods are documented in the
Statistical Analysis Plan.11. Study devices
The investigational device to be used in this trial is the Absorb BVS.
Absorb BVS is composed of a poly-L-lactic acid (PLLA) backbone, coated
with a matrix composed of the drug everolimus and poly-D, L-lactic acid
(PDLLA) in a 1:1 ratio. Approximately 80% of the drug is eluted within
28 days. Both PLLA and PDLLA are fully bioresorbable, with PDLLA ex-
pected to be totally bioresorbed by the body in 9 months and PLLA in
36 months. Preclinical testing suggests that neither PDLLA nor PLLA re-
main in the body after the specified period. Absorb BVS ismanufactured
by Abbott Cardiovascular Systems, Inc., a subsidiary of Abbott Vascular,
Inc. and received CE-mark approval in January 2011.
The control device is the Xience family everolimus eluting coronary
stent, which is also manufactured by Abbott Cardiovascular Systems,
Inc., a subsidiary of Abbott Vascular, Inc. and received CE-mark approval
in 2007. The control device is considered to be the current standard for
DES given its documented clinical performance and safety.12. Index and staged procedures
To assess the eligibility of the subject according to the inclusion
criteria, the target vessel diameter and the lesion characteristics
must be visually evaluated before randomization. Because of the lim-
ited available size matrix of the Absorb BVS, the reference vessel di-
ameter of the target lesion(s) should be ≥2.50 mm and ≤4 mm. In
case the vessel size is estimated to be ≤2.75mm or lower by visual as-
sessment, quantitative vessel sizing by QCA, IVUS or OCT is manda-
tory to ascertain that the reference vessel size is ≥2.50 mm in order
to exclude small vessels with documented increased TLF and scaffold
thrombosis rates. When randomized to the Absorb BVS arm, pre-
dilatation of the target lesions is mandatory with a balloon of equal
size to the reference vessel diameter (ratio 1:1). Usage of non-
compliant balloon is recommended. The Absorb BVS must be de-
ployed slowly in 2 atm increments every 5 s, per Instructions for
Use. Post-scaffold high-pressure (≥16 atm) dilatation is strongly rec-
ommended in all cases, with nominal diameter of the post-dilatation
balloon of the same size, or ≤ 0.5mm larger as the implanted scaffold.
For long target lesions, abutting/overlapping of two scaffolds is
allowed and the overlapped segment should be a maximum of
1.5 mm. Bifurcation lesions are recommended to be treated with a
provisional single scaffold strategy, although fenestration of a side
branch may be performed with a ≤2.5 mm balloon [23]; two-
scaffold strategies with Absorb BVS are not allowed in this trial. De-
ployment of Xience EES should be performed according to Instruc-
tion for Use (IFU). Post-dilatation for subjects treated with Xience
EES will be done according to the IFU and operators' discretion.
It is strongly recommended that all lesions in the target vessel are
treated in the same procedure, except in patients presenting with ST
elevation myocardial infarction (STEMI). In STEMI patients, it is
highly recommended that non-culprit lesions are treated at a staged
procedure unless clinically indicated. Staged procedures are allowed
but should be completed within 6 weeks and mentioned at the index
procedure. All lesions should be treated with the assigned type of
stent or scaffold. Moreover, all the staged procedures should be de-
clared at the time of or after the index procedure. Treatment of
non-target lesions may be performed during the same PCI procedure
before randomization. However, patients can be randomized only
after all such lesions have been successfully treated without compli-
cation. In case of a non-successful or complicated non-target lesion
treatment the patient may not be enrolled into the trial. Only after
a minimum of 30 days post treatment of such non-target lesions
may the patient undergo index treatment of the target lesion
(s) and be enrolled into the trial. In this case, pre-procedural cardiac
biomarkers should have returned to normal and it should be checked
that the patient still fulfils inclusion criteria.
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In the Absorb BVS-treated group, patients presentingwith acute cor-
onary syndrome (ACS), patients will continue dual antiplatelet therapy
(DAPT)with prasugrel or ticagrelor (clopidogrel if neither available) for
a minimum of 12 months; after this period, DAPT may be continued to
36 months, except in patients who are at high bleeding risk. For non-
ACS presentations, DAPT should be continued for a minimum of
6 months, again continuing to 36 months when bleeding risk permits.
In the Xience EES group, patients should continue DAPT for a mini-
mum of 12 months with prasugrel or ticagrelor (clopidogrel if both
not available) for ACS presentations, and for a minimum of 6 months
in patients with stable angina. Prolonged DAPTmay be prescribed, con-
sidering the bleeding and thrombo-ischemic risk of individual patients.
14. Clinical follow-up
Hospital visits are planned at 1, 6- and 12-month post-procedure, at
which time assessments of anginal status, cardiovascular drug use and
any serious adverse events will be made. Annual phone contacts are
then scheduled up to 7 years.
Detailed Quality of Life (EQ5D) and Seattle Angina Questionnaires
will be recorded (SAQ) at 30, 180- and 360-day post-procedure and at
the time of any recurrent event. Chest pain symptoms potentially re-
lated to angina will be assessed using a dedicated structured question-
naire at 1, 6 and 12 months and at intermittent events. In addition,
major costs related to diagnostic workups or therapies triggered by
symptoms of chest pain will be collected in the first year. After
12 months, major costs related to treatment and target vessel failure
will be collected. The cost-effectiveness of the two treatment arms re-
lated to chest pain or angina will be assessed at 12 months using unit
costs in 5 countries.
15. Safety monitoring by data safety monitoring board
The Data SafetyMonitoring Board (DSMB)will monitor the safety of
subjects and/or efficacy of treatments throughout the subject enrolment
and on an ongoing basis. The composition, guiding policies, and operat-
ing procedures governing the DSMB are described in a separate DSMB
charter. Based on safety data, the DSMB may recommend the Steering
Committee to modify or stop the clinical trial/investigation. All final de-
cisions regarding clinical trial/investigation modifications, however,
rest with the Steering Committee.
16. Adjudication of events
Events will be adjudicated by the clinical event committee (CEC),
which is comprised of qualified physicians who are not investigators in
the trial. The CEC will be responsible for adjudicating all serious adverse
events (SAE). The composition, guiding policies, and operating procedures
governing the CEC are described in a separate CEC manual of operations.
17. Enrolment status and updated protocol
The enrolment of COMPARE ABSORB trial started in September 2015.
In the original protocol, primary hypothesis I was a non-inferiority end-
point comparing Absorb BVSwith Xience EES in terms of TLF at l year. Pri-
mary hypothesis II was the superiority of Absorb BVS over Xience EES in
TLF between 1 and 5 years, based on the assumption that the event rate
will continue to increase in the Xience EES armbutwill downswing or re-
main constant in the Absorb BVS arm after 1 year. However, during the
enrolment of patients in COMPAREABSORB, follow-up results of early Ab-
sorb trials have shown that the event rate continued to increase in Absorb
BVS-treated patients from 1 to 3 years, and that the scaffolds appeared to
still be present in imaged coronary arteries, implying that Absorb BVS
were not completely absorbed as had been expected. In addition, theresults of ABSORB III and AIDA showed that patients treated with Absorb
BVS experienced a significantly higher definite or probable stent/scaffold
thrombosis rate than Xience EES arm. Because of this safety concern, the
Steering Committee decided to discontinue patient enrolment on 31st
August 2017. At that time, the trial already enrolled 1670 patients to ex-
amine the primary hypothesis I. According to the 5-year follow-up data
from Absorb cohort B, the curve of major adverse cardiovascular events
(MACE) appears flat from 3 years and afterwards, and therefore, the
long-termbenefit of the Absorb BVS could be exhibited at such prolonged
timepoints. Therefore, the timing of landmark analysis of the primary hy-
pothesis IIwas revised to between3 and7 years, instead of between1 and
5 years. This trial still has 80% power to show the superiority of Absorb
BVS over Xience EES even if relative risk ratio from 3 to 7 years of Absorb
BVS against Xience EES is 0.65. This change is in line with the recent pro-
tocol revisions of the ABSORB III and IV trials (NCT02173379).
The other major change in the COMPARE ABSORB protocol is the in-
clusion criteria for small vessels: initially, the protocol allowed inclusion
of target vessels with reference diameter equal to 2.25 mm. However,
because of the safety issue in the small vessel subset raised in the Absorb
BVS arm of the ABSORB III trial, the Steering Committee decided to ex-
clude target lesions with reference vessel diameter b2.5 mm. In the
meantime, results from the ABSORB II and AIDA trials demonstrated
that there was a maintained risk of scaffold thrombosis in Absorb BVS
arm, especially between 1 and 3 years, and it was therefore suggested
that use of extended DAPT regimes in patients treated with Absorb
BVS up to 3 years could be justified on an individual patient basis. Al-
though there is limited evidence to support extended DAPT treatment
after Absorb BVS implantation, the Steering Committee decided to in-
form enrolled patients about the type of device they received and pro-
long the DAPT use up to 3 years on an empirical basis.
For the metallic stent arm, the DAPT study demonstrated that ex-
tended DAPT therapy up to 30 months, as compared with aspirin ther-
apy alone, significantly reduced risks of stent thrombosis and major
adverse cardiovascular and cerebrovascular events but was associated
with an increased risk of bleeding [24]. The PEGASUS-TIMI 54 trial
[25] evaluated long-term therapy with ticagrelor in addition to aspirin,
in patients with a history of spontaneousMI occurring 1 to 3 years prior
to randomization and concluded that ticagrelor significantly reduced
the risk of MACE compared with placebo. Recently, a meta-analysis
showed that DAPT beyond 1 year among stabilized high-risk patients
with prior MI decreased ischemic events, but increased major bleeding
[26]. In light of such study results, theACC/AHA focused update onDAPT
recommended that DAPT for longer than 6months after implantation of
a DES may be reasonable for patients with stable ischemic heart disease
who are not at high risk of bleeding and who tolerated DAPT without
bleeding complications (Class IIb recommendation) [27].
18. Limitations
In our study design, SCAI consensus was adopted to adjudicate
periprocedural MI which is more clinically relevant in terms of progno-
sis. This definition of periprocedural MI is different from that of the ref-
erence trial, the RESOLUTE-AC [22]. Although the expected impact of
this difference is limited [28], it could be a potential risk for underesti-
mation of the event rate.
19. Conclusions and perspective
The COMPARE ABSORB trial is the only prospective randomized
head-to-head comparison of Absorb BVS with best-in-class metallic
EES in high risk patient/lesion subsets, reflective of everyday PCI prac-
tice. The study also incorporates a recommendation for best-practice
implantation technique (‘PSP’) in the study protocol. These factors
make this stud unique and scientifically important in furthering our un-
derstanding of use of a BVS platform in routine PCI.
582 C.C. Chang et al. / Cardiovascular Revascularization Medicine 20 (2019) 577–582Although there is no scientific evidence that prolonged DAPT use
will reduce the risk of scaffold thrombosis to date, the COMPARE AB-
SORB trial also aims to evaluate the effectiveness and safety of extended
DAPT duration up to 3 years after Absorb BVS implantation.
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